The metabolite GLP‐1 (9‐36) is neuroprotective and anti‐inflammatory in cellular models of neurodegeneration
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Glucagon‐like peptide‐1 (GLP‐1) is best known for its insulinotropic action following food intake. Its metabolite, GLP‐1 (9‐36), was assumed biologically inactive because of low GLP‐1 receptor (GLP‐1R) affinity and non‐insulinotropic properties; however, recent studies contradict this assumption. Increased use of FDA approved GLP‐1 analogues for treating metabolic disorders and neurodegenerative diseases raises interest in GLP‐1 (9‐36)’s biological role. We use human SH‐SY5Y neuroblastoma cells and a GLP‐1R over‐expressing variety (#9), in both undifferentiated and differentiated states, to evaluate the neurotrophic/neuroprotective effects of GLP‐1 (9‐36) against toxic glutamate exposure and other oxidative stress models (via the MTS, LDH or ROS assays). In addition, we examine GLP‐1 (9‐36)’s signaling pathways, including cyclic‐adenosine monophosphate (cAMP), protein kinase‐A (PKA), and 5’ adenosine monophosphate‐activated protein kinase (AMPK) via the use of ELISA, pharmacological inhibitors, or GLP‐1R antagonist. Human HMC3 and mouse IMG microglial cell lines were used to study the anti‐inflammatory effects of GLP‐1 (9‐36) against lipopolysaccharide (LPS) (via ELISA). Finally, we applied GLP‐1 (9‐36) to primary dissociation cultures challenged with α‐synuclein or amyloid‐β and assessed survival and morphology via immunochemistry. We demonstrate evidence of GLP‐1R, cAMP, PKA, and AMPK‐mediated neurotrophic and neuroprotective effects of GLP‐1 (9‐36). The metabolite significantly reduced IL‐6 and TNF‐α levels in HMC3 and IMG microglial cells, respectively. Lastly, we show mild but significant effects of GLP‐1 (9‐36) in primary neuron cultures challenged with α‐synuclein or amyloid‐β. These studies enhance understanding of GLP‐1 (9‐36)’s effects on the nervous system and its potential as a primary or complementary treatment in pathological contexts. image
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurotoxic reactive astrocytes are induced by activated microglia
Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., et al. (2017) · Nature · doi:10.1038/nature21029 · Cited by 7,971
How to calculate sample size in animal studies?
Charan, J., & Kantharia, N. D. (2013) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.119726 · Cited by 1,881 · cited 1×
“The sample size was selected based on our prior studies (Li et al., 2017, 2020, 2009) and a power analysis (Charan & Kantharia, 2013).”
MethodNauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Zhang, W., Wang, T., Pei, Z., Miller, D. S., Wu, X., Block, M. L., Wilson, B., Zhang, W., Zhou, Y., Hong, J.-S., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-2751com · Cited by 1,265 · cited 3×
“…0.05; **p < 0.01; ****p < 0.0001; Statistical comparison vs. H2O2 alone group: #p < 0.05; ##p < 0.01) (scale bar = 50 µm) or Ex- 4 for 24 h and then challenged with oligomeric α- syn (250 nM for 48 h (Zhang et al., 2005)) to induce an unsurmountable neuronal loss of approximately 36.4% (Figure 8a).”
MethodInfluentialBlock of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease
Yun, S. P., Kam, T.-I., Panicker, N., Kim, S., Oh, Y., Park, J.-S., Kwon, S.-H., Park, Y. J., Karuppagounder, S. S., Park, H., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0051-5 · Cited by 1,123
Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000
Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889 · cited 1×
“…in reversing dopaminergic cell death in animal models of PD (Chen et al., 2018; Glotfelty et al., 2020; Li et al., 2009; Salcedo et al., 2012) and recently have shown benefits in a human PD clinical trial (Athauda et al., 2017), with further ones planned or ongoing (Glotfelty et al., 2020).”
BackgroundSelf-citationPyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876 · cited 1×
“Whereas, the GLP- 1 receptor (GLP- 1R) resides ubiquitously in the pancreas, it is also expressed in other tissues (Pyke et al., 2014), including the brain where its activation produces cell- typespecific pleiotropic effects (Rowlands et al., 2018).”
BackgroundNAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · cited 1×
“…blood sugar homeostasis and insulin release is largely driven by the postprandially produced incretin signaling hormones, including glucagon- like peptide- 1 (GLP- 1) (Nauck et al., 1986), and deficits in incretin signaling are hallmarks of type- 2 diabetes mellitus (T2DM) (Holst & Ørskov, 2004).”
BackgroundInsulin and neurodegenerative disease: shared and specific mechanisms
Craft, S., & Stennis Watson, G. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00681-7 · Cited by 830
Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589 · cited 5×
“…have previously demonstrated efficacy in reversing dopaminergic cell death in animal models of PD (Chen et al., 2018; Glotfelty et al., 2020; Li et al., 2009; Salcedo et al., 2012) and recently have shown benefits in a human PD clinical trial (Athauda et al., 2017), with further ones…”
BackgroundMethodInfluentialSelf-citationGejl, M., Gjedde, A., Egefjord, L., Møller, A., Hansen, S. B., Vang, K., Rodell, A., Brændgaard, H., Gottrup, H., Schacht, A., et al. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00108 · Cited by 480
Richards, P., Parker, H. E., Adriaenssens, A. E., Hodgson, J. M., Cork, S. C., Trapp, S., Gribble, F. M., & Reimann, F. (2014) · Diabetes · doi:10.2337/db13-1440 · Cited by 472 · cited 2×
“The role of GLP- 1 (9- 36) has yet to be fully characterized, and it was once considered to be an inert waste product, although it may be a primary agonist for GLP- 1Rs that exist within the peripheral (PNS) and central nervous system (CNS) (Richards et al., 2014).”
BackgroundAthauda, D., & Foltynie, T. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.013 · Cited by 383 · cited 1×
“…have efficacy in treating a variety of neurological disorders, including traumatic brain injury (Glotfelty et al., 2019; Greig et al., 2014), PD (Athauda & Foltynie, 2016; Glotfelty et al., 2020; Kim et al., 2017), AD (Hölscher, 2020), stroke (Chen et al., 2018; Li et al., 2009; Zhang et al.,…”
BackgroundProtection and Reversal of Excitotoxic Neuronal Damage by Glucagon-Like Peptide-1 and Exendin-4
Perry, T., Haughey, N. J., Mattson, M. P., Egan, J. M., & Greig, N. H. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.037481 · Cited by 380 · cited 1×
“…clinically as a glucoregulatory agent for T2DM treatment, its neurotrophic and neuroprotective properties became evident (Gilman et al., 2003; Perry et al., 2002, 2003; Perry, Lahiri, et al., 2002) and sparked interest in utilizing incretins as potential treatments for neurological disorders…”
BackgroundSelf-citationPleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302 · cited 3×
“GLP- 1R activation is known to activate a variety of downstream neuroprotective secondary messengers, most notably cAMP (Rowlands et al., 2018).”
BackgroundCukierman-Yaffe, T., Gerstein, H. C., Colhoun, H. M., Diaz, R., García-Pérez, L.-E., Lakshmanan, M., Bethel, A., Xavier, D., Probstfield, J., Riddle, M. C., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30173-3 · Cited by 300
Circulation and Degradation of GIP and GLP-1
Deacon, C. F. (2004) · Hormone and Metabolic Research · doi:10.1055/s-2004-826160 · Cited by 299
Diabetes medications and risk of Parkinson’s disease: a cohort study of patients with diabetes
Brauer, R., Wei, L., Ma, T., Athauda, D., Girges, C., Vijiaratnam, N., Auld, G., Whittlesea, C., Wong, I., & Foltynie, T. (2020) · Brain · doi:10.1093/brain/awaa262 · Cited by 233
Brain insulin resistance: role in neurodegenerative disease and potential for targeting
Hölscher, C. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1738383 · Cited by 180
Wei, R., Ma, S., Wang, C., Ke, J., Yang, J., Li, W., Liu, Y., Hou, W., Feng, X., Wang, G., et al. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00400.2015 · Cited by 137 · cited 1×
“This can occur independently (Han et al., 2019) or in conjunction (Wei et al., 2016) with the commonly described GLP- 1R- mediated activation of cAMP.”
BackgroundKim, D. S., Choi, H.-I., Wang, Y., Luo, Y., Hoffer, B. J., & Greig, N. H. (2017) · Cell Transplantation · doi:10.1177/0963689717721234 · Cited by 136
Self-citationMeier, J. J., Gethmann, A., Nauck, M. A., Götze, O., Schmitz, F., Deacon, C. F., Gallwitz, B., Schmidt, W. E., & Holst, J. J. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00576.2005 · Cited by 104 · cited 1×
“This effect may be species specific as it was not observed in mice (Rolin et al., 2004) but was evident in pigs (Deacon et al., 2002) and humans (Meier et al., 2006).”
BackgroundGLP-1 receptor agonists in diabetes for stroke prevention: a systematic review and meta-analysis
Malhotra, K., Katsanos, A. H., Lambadiari, V., Goyal, N., Palaiodimou, L., Kosmidou, M., Krogias, C., Alexandrov, A. V., & Tsivgoulis, G. (2020) · Journal of Neurology · doi:10.1007/s00415-020-09813-4 · Cited by 65
Cited by
Kim, C. H. (2023) · Cellular & Molecular Immunology · doi:10.1038/s41423-023-00987-1 · Cited by 420
Kopp, K. O., Glotfelty, E. J., Li, Y., & Greig, N. H. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106550 · Cited by 298
Self-citationAnti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases
Diz-Chaves, Y., Mastoor, Z., Spuch, C., González-Matías, L. C., & Mallo, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179583 · Cited by 148
“However, in vitro studies have demonstrated that its metabolite, GLP-1(9–36), has protective effects in neuronal and microglial cell lines [41].”
BackgroundGLP-1 receptor agonist as a modulator of innate immunity
Chen, J., Mei, A., Wei, Y., Li, C., Qian, H., Min, X., Yang, H., Dong, L., Rao, X., & Zhong, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.997578 · Cited by 120
“Glucagon-like peptide-1 (GLP-1) is an endogenous incretin secreted by small intestinal L cells, consisting of two bioactive isoforms: GLP-1 (7-37) and GLP-1 (736).”
BackgroundRole of glucagon-like peptide-1 receptor agonists in Alzheimer’s disease and Parkinson’s disease
Hong, C.-T., Chen, J.-H., & Hu, C.-J. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-01090-x · Cited by 78
Metadata
- Authors
- Li, Y., Glotfelty, E. J., Karlsson, T., Fortuno, L. V., Harvey, B. K., & Greig, N. H.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2021-10-21
- Volume
- 159
- Issue
- 5
- Pages
- 867-886
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W3203222544
- Cited by
- 47
- References
- 24
- FWCI
- 2.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.